BACKGROUND AND OBJECTIVES:Donor dopamine improves initial graft functionafter kidney transplantation due to antioxidant properties. We investigated if a 4 µg/kg per minute continuous dopamine infusion administered after brain-death confirmation affects long-term graft survival and examined the exposure-response relationship with treatment duration. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Five-year follow-up of 487 renal transplant patients from 60 European centers who had participated in the randomized, multicenter trial of dopamine donor pretreatment between 2004 and 2007 (ClinicalTrials.gov identifier: NCT00115115). RESULTS: Follow-up was complete in 99.2%. Graft survival was 72.6% versus 68.7% (P=0.34), and 83.3% versus 80.4% (P=0.42) after death-censoring in treatment and control arms according to trial assignment. Although infusion times varied substantially in the treatment arm (range 0-32.2 hours), duration of the dopamine infusion and all-cause graft failure exhibited an exposure-response relationship (hazard ratio, 0.96; 95% confidence interval [95% CI], 0.92 to 1.00, per hour). Cumulative frequency curves of graft survival and exposure time of the dopamine infusion indicated a maximum response rate at 7.10 hours (95% CI, 6.99 to 7.21), which almost coincided with the optimum infusion time for improvement of early graft function (7.05 hours; 95% CI, 6.92 to 7.18). Taking infusion time of 7.1 hours as threshold in subsequent graft survival analyses indicated a relevant benefit: Overall, 81.5% versus 68.5%; P=0.03; and 90.3% versus 80.2%; P=0.04 after death-censoring. CONCLUSIONS: We failed to show a significant graft survival advantage on intention-to-treat. Dopamine infusion time was very short in a considerable number of donors assigned to treatment. Our finding of a significant, nonlinear exposure-response relationship disclosed a threshold value of the dopamine infusion time that may improve long-term kidney graft survival.
RCT Entities:
BACKGROUND AND OBJECTIVES:Donordopamine improves initial graft function after kidney transplantation due to antioxidant properties. We investigated if a 4 µg/kg per minute continuous dopamine infusion administered after brain-death confirmation affects long-term graft survival and examined the exposure-response relationship with treatment duration. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Five-year follow-up of 487 renal transplant patients from 60 European centers who had participated in the randomized, multicenter trial of dopaminedonor pretreatment between 2004 and 2007 (ClinicalTrials.gov identifier: NCT00115115). RESULTS: Follow-up was complete in 99.2%. Graft survival was 72.6% versus 68.7% (P=0.34), and 83.3% versus 80.4% (P=0.42) after death-censoring in treatment and control arms according to trial assignment. Although infusion times varied substantially in the treatment arm (range 0-32.2 hours), duration of the dopamine infusion and all-cause graft failure exhibited an exposure-response relationship (hazard ratio, 0.96; 95% confidence interval [95% CI], 0.92 to 1.00, per hour). Cumulative frequency curves of graft survival and exposure time of the dopamine infusion indicated a maximum response rate at 7.10 hours (95% CI, 6.99 to 7.21), which almost coincided with the optimum infusion time for improvement of early graft function (7.05 hours; 95% CI, 6.92 to 7.18). Taking infusion time of 7.1 hours as threshold in subsequent graft survival analyses indicated a relevant benefit: Overall, 81.5% versus 68.5%; P=0.03; and 90.3% versus 80.2%; P=0.04 after death-censoring. CONCLUSIONS: We failed to show a significant graft survival advantage on intention-to-treat. Dopamine infusion time was very short in a considerable number of donors assigned to treatment. Our finding of a significant, nonlinear exposure-response relationship disclosed a threshold value of the dopamine infusion time that may improve long-term kidney graft survival.
Authors: D J Malinoski; M S Patel; O Ahmed; M C Daly; S Mooney; C O Graybill; C E Foster; A Salim Journal: Am J Transplant Date: 2013-02-13 Impact factor: 8.086
Authors: Paul-Thomas Brinkkoetter; Grietje C Beck; Uwe Gottmann; Ralf Loesel; Ulf Schnetzke; Boris Rudic; Christine Hanusch; Neysan Rafat; Zhenzi Liu; Christel Weiss; Henri G D Leuvinik; Rutger Ploeg; Claude Braun; Peter Schnuelle; Fokko J van der Woude; Benito A Yard Journal: Transplantation Date: 2006-08-27 Impact factor: 4.939
Authors: Peter Schnuelle; Uwe Gottmann; Simone Hoeger; Detlef Boesebeck; Werner Lauchart; Christel Weiss; Michael Fischereder; Karl-Walter Jauch; Uwe Heemann; Martin Zeier; Christian Hugo; Przemyslaw Pisarski; Bernhard K Krämer; Kai Lopau; Axel Rahmel; Urs Benck; Rainer Birck; Benito Antonio Yard Journal: JAMA Date: 2009-09-09 Impact factor: 56.272
Authors: P Schnuelle; B A Yard; C Braun; E Dominguez-Fernandez; M Schaub; R Birck; J Sturm; S Post; F J van der Woude Journal: Am J Transplant Date: 2004-03 Impact factor: 8.086
Authors: Carl-Ludwig Fischer-Fröhlich; Marcus Kutschmann; Johanna Feindt; Irene Schmidtmann; Günter Kirste; Nils R Frühauf; Ulrike Wirges; Axel Rahmel; Christina Schleicher Journal: J Transplant Date: 2015-10-11
Authors: Isabela R Zanetti; Michelle Burgin; Liqiang Zhang; Steve T Yeh; Sriram Ambadapadi; Jacquelyn Kilbourne; Jordan R Yaron; Kenneth M Lowe; Juliane Daggett-Vondras; David Fonseca; Ryan Boyd; Dara Wakefield; William Clapp; Efrem Lim; Hao Chen; Alexandra Lucas Journal: Pathogens Date: 2022-05-16
Authors: Andreas L H Gerken; Kai Nowak; Alexander Meyer; Christel Weiss; Bernd Krüger; Nina Nawroth; Ioannis Karampinis; Katharina Heller; Hendrik Apel; Christoph Reissfelder; Kay Schwenke; Michael Keese; Werner Lang; Ulrich Rother Journal: Ann Surg Date: 2020-12-30 Impact factor: 13.787
Authors: Roman Reindl-Schwaighofer; Alexander Kainz; Kira Jelencsics; Andreas Heinzel; Gabriela Berlakovich; Ádám Remport; Georg Heinze; Robert Langer; Rainer Oberbauer Journal: Am J Transplant Date: 2019-02-01 Impact factor: 8.086